September 2024 in “Cureus” Guselkumab effectively treats skin reactions caused by adalimumab in certain conditions.
11 citations
,
November 2021 in “JDDG Journal der Deutschen Dermatologischen Gesellschaft” Cutaneous angiosarcomas require a combined treatment approach, but prognosis is generally poor.
March 2022 in “Oncology Times” Tebentafusp-tebn improves survival rates in uveal melanoma patients but has common side effects like rash and fatigue.
16 citations
,
April 2014 in “Expert Opinion on Pharmacotherapy” Teriflunomide is an effective and safe first-line oral treatment for relapsing multiple sclerosis.
4 citations
,
August 2025 in “Journal of Food Science” Tremella fuciformis polysaccharide has many health benefits and potential uses in food, medicine, and cosmetics.
36 citations
,
June 2014 in “Experimental Neurology” Teriflunomide is an effective and generally safe oral treatment for relapsing MS, reducing relapses and slowing disability progression.
September 2013 in “Neurodegenerative disease management” Teriflunomide is effective and generally safe for treating relapsing multiple sclerosis, reducing relapse rates and disability progression.
28 citations
,
October 2010 in “Targeted Oncology” Trastuzumab may cause tufted hair folliculitis as a side effect.
20 citations
,
December 2016 in “Neurodegenerative disease management” Teriflunomide effectively reduces relapses and disability in MS and has a manageable safety profile.
2 citations
,
June 2019 in “Boletín médico del Hospital Infantil de México” Tofacitinib treatment is used for teenagers with alopecia areata.
3 citations
,
April 2021 in “Oncology Times” Trodelvy™ helped some patients with advanced breast cancer, but had side effects.
October 2012 in “한국미용학회지” Tremella fuciformis Berk helps protect hair growth from stress effects.
29 citations
,
January 2016 in “CNS drugs” Teriflunomide is effective and generally safe for treating relapsing-remitting multiple sclerosis.
22 citations
,
February 2023 in “European Journal of Neurology” Fremanezumab effectively reduces migraines and improves quality of life with mild side effects.
188 citations
,
October 2014 in “Thyroid” Dabrafenib was effective and well tolerated in treating thyroid cancer with a specific mutation.
The combination of high-dose toremifene and capecitabine was effective for advanced recurrent breast cancer.
2 citations
,
April 2019 in “Dermatologic Therapy” A patient with alopecia had hair regrowth with tofacitinib but developed a skin reaction, choosing to continue the treatment despite the side effect.
October 2020 in “Der Hautarzt” Tofacitinib helped regrow hair in a woman with alopecia areata.
39 citations
,
September 2015 in “Clinical Therapeutics” Teriflunomide effectively reduces relapse rates and disease progression in multiple sclerosis but is not safe for use during pregnancy.
13 citations
,
November 2021 in “Pediatric Dermatology” Tofacitinib taken by mouth helps treat hair loss in children.
5 citations
,
March 2021 in “Hepatitis Monthly” Tenofovir alafenamide fumarate is effective and safer for hepatitis B, with fewer side effects than tenofovir disoproxil fumarate.
August 2025 in “Journal of the American Academy of Dermatology”
139 citations
,
November 2016 in “Journal of the American Academy of Dermatology” Tofacitinib helped regrow hair in most adolescents with alopecia areata, but more research is needed.
5 citations
,
January 2021 in “Inflammatory Bowel Diseases” Tofacitinib improved ulcerative colitis, skin ulcers, and hair loss in a patient who didn't respond well to other treatments.
June 2025 in “British Journal of Dermatology” Tofacitinib was more effective than methotrexate for treating alopecia areata.
1 citations
,
January 2012 in “Jounal of The Korean Society of cosmetology” Tremella fuciformis Berk helps protect hair from stress-related damage.
July 2025 in “Clinical Medicine” Oral betamethasone works faster than oral tofacitinib for hair regrowth in alopecia areata.
January 2016 in “The Australian Pharmacist” Tofacitinib might be used to treat hair loss.
September 2023 in “Journal of the American Academy of Dermatology” CTP-543 is generally safe for treating alopecia areata.
1 citations
,
May 2021 in “Annals of the rheumatic diseases” Tofacitinib is a promising treatment for children with rheumatic diseases.